Protection and selection for gene therapy in the hematopoietic system.
| dc.contributor.author | Milsom, Michael D | |
| dc.contributor.author | Fairbairn, Leslie J | |
| dc.date.accessioned | 2009-08-25T11:04:22Z | |
| dc.date.available | 2009-08-25T11:04:22Z | |
| dc.date.issued | 2004-02 | |
| dc.identifier.citation | Protection and selection for gene therapy in the hematopoietic system. 2004, 6 (2):133-46 J Gene Med | en |
| dc.identifier.issn | 1099-498X | |
| dc.identifier.pmid | 14978767 | |
| dc.identifier.doi | 10.1002/jgm.533 | |
| dc.identifier.uri | http://hdl.handle.net/10541/78442 | |
| dc.description.abstract | Hematopoietic stem cell gene therapy is potentially curative for a number of inherited and acquired disorders. However, poor gene transfer and expression in repopulating hematopoietic stem cells attenuate this potential. Here we review potential means of conferring a selective advantage to hematopoietic stem cells and their progeny, and discuss the issues that surround the use of selective advantages in vivo. | |
| dc.language.iso | en | en |
| dc.subject | Haematopoietic System | en |
| dc.subject.mesh | ATP-Binding Cassette Transporters | |
| dc.subject.mesh | Animals | |
| dc.subject.mesh | DNA Modification Methylases | |
| dc.subject.mesh | DNA Repair | |
| dc.subject.mesh | Drug Resistance | |
| dc.subject.mesh | Gene Therapy | |
| dc.subject.mesh | Hematopoietic System | |
| dc.subject.mesh | Homeodomain Proteins | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Tetrahydrofolate Dehydrogenase | |
| dc.subject.mesh | Transcription Factors | |
| dc.title | Protection and selection for gene therapy in the hematopoietic system. | en |
| dc.type | Article | en |
| dc.contributor.department | Cancer Research UK Gene Therapy Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. | en |
| dc.identifier.journal | The Journal of Gene Medicine | en |
| html.description.abstract | Hematopoietic stem cell gene therapy is potentially curative for a number of inherited and acquired disorders. However, poor gene transfer and expression in repopulating hematopoietic stem cells attenuate this potential. Here we review potential means of conferring a selective advantage to hematopoietic stem cells and their progeny, and discuss the issues that surround the use of selective advantages in vivo. |